Controversial results of therapy with mesenchymal stem cells in the acute phase of canine distemper disease

19 de março de 2021

Resultados controversos da terapia com células-tronco mesenquimais na fase aguda fase da cinomose canina


A.O. Pinheiro, M.T. Cardoso, A.S. Vidane, J.B. Casals, D. Passarelli, A.L.F. Alencar, R.L.M. Sousa, P. Fantinato-Neto, V.C. Oliveira, V.M. Lara, C.E. Ambrósio.


Distemper disease is an infectious disease reported in several species of domestic and wild carnivores. The high mortality rate of animals infected with canine distemper virus (CDV) treated with currently available therapies has driven the study of new efficacious treatments. Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic option for many degenerative, hereditary, and inflammatory diseases. Therefore, the aim of this study was to characterize stem cells derived from the canine fetal olfactory epithelium and to assess the systemic response of animals infected with CDV to symptomatic therapy and treatment with MSCs. Eight domestic mongrel dogs (N = 8) were divided into two groups: support group (SG) (N = 5) and support group + cell therapy (SGCT) (N = 3), which were monitored over 15 days. Blood samples were collected on days 0, 6, 9, 12, and 15 to assess blood count and serum biochemistry (urea, creatinine, alanine transferase, alkaline phosphatase, gammaglutamyl transferase, total protein, albumin, and globulin), and urine samples were obtained on days 0 and 15 for urinary evaluation (urine I). The results showed a high mortality rate (SG = 4 and SGCT = 2), providing inadequate data on the clinical course of CDV infection. MSC therapy resulted in no significant improvement when administered during the acute phase of canine distemper disease, and a prevalence of animals with high mortality rate was found in both groups due to the severity of symptoms.


Canine distemper; Infectious; Stem cells; Treatment; Virus


Cinomose Canina; Infeccioso; Células-tronco; Tratamento; Vírus

Comentar este artigo

Você precisa estar logado para comentar os artigos.
Desenvolvido por logo-crowd